Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
Rhea-AI Summary
Nautilus Biotechnology (NASDAQ: NAUT) will report first quarter 2026 financial results before market open on April 28, 2026. Management will host a webcast and conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss results, business developments, and outlook. Live audio will be available on the company Investors website.
Positive
- None.
Negative
- None.
News Market Reaction – NAUT
In the Apr 9 session, NAUT declined 2.88%, reflecting a moderate negative market reaction. Argus tracked a trough of -13.2% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Earnings date notice | Neutral | -2.9% | Scheduled Q4 and FY2025 results with webcast details before market open. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited earnings-date history: the prior notice of results on Feb 5, 2026 saw a -2.88% move.
Recent news for Nautilus highlighted platform and commercialization progress: unveiling the Voyager platform with capacity for up to 10 billion proteins per run, launching an Early Access Program in Jan 2026, and signing Baylor College of Medicine as the first Early Access customer. The Feb 2025 earnings release showed FY2025 operating expenses of $66.8M and cash of $156.1M, with guidance for 15–20% opex growth and no material Early Access revenue expected in 2026. Today’s announcement simply schedules the next earnings date, consistent with prior practices.
Key Terms
single-molecule protein analysis platform technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter 2026 before market open on Tuesday, April 28, 2026.
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio